MersV1, Main, Exploration, bibRecord, 001497

[Small molecular agents against MERS-CoV infection].

Identifieur interne : 001497 ( Main/Exploration ); précédent : 001496; suivant : 001498

[Small molecular agents against MERS-CoV infection].

Auteurs : Xiao-Yun Zeng ; Lu Lu ; Shi-Bo Jiang ; Shu-Wen Liu

Source :

Yao xue xue bao = Acta pharmaceutica Sinica [ 0513-4870 ] ; 2015.

RBID : pubmed:27169271

Descripteurs français

KwdFr :
- Anticorps monoclonaux (pharmacologie), Antiviraux (pharmacologie), Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient (), Humains, Infections à coronavirus (traitement médicamenteux).
MESH :
- pharmacologie : Anticorps monoclonaux, Antiviraux.
- traitement médicamenteux : Infections à coronavirus.
- Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains.

English descriptors

KwdEn :
- Antibodies, Monoclonal (pharmacology), Antiviral Agents (pharmacology), Coronavirus Infections (drug therapy), Drug Design, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects).
MESH :
- chemical , pharmacology : Antibodies, Monoclonal, Antiviral Agents.
- drug effects : Middle East Respiratory Syndrome Coronavirus.
- drug therapy : Coronavirus Infections.
- Drug Design, Humans.

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.

PubMed: 27169271

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Small molecular agents against MERS-CoV infection].</title>
<author><name sortKey="Zeng, Xiao Yun" sort="Zeng, Xiao Yun" uniqKey="Zeng X" first="Xiao-Yun" last="Zeng">Xiao-Yun Zeng</name>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
</author>
<author><name sortKey="Jiang, Shi Bo" sort="Jiang, Shi Bo" uniqKey="Jiang S" first="Shi-Bo" last="Jiang">Shi-Bo Jiang</name>
</author>
<author><name sortKey="Liu, Shu Wen" sort="Liu, Shu Wen" uniqKey="Liu S" first="Shu-Wen" last="Liu">Shu-Wen Liu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:27169271</idno>
<idno type="pmid">27169271</idno>
<idno type="wicri:Area/PubMed/Corpus">001122</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001122</idno>
<idno type="wicri:Area/PubMed/Curation">001122</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001122</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001264</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001264</idno>
<idno type="wicri:Area/Ncbi/Merge">001623</idno>
<idno type="wicri:Area/Ncbi/Curation">001623</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001623</idno>
<idno type="wicri:doubleKey">0513-4870:2015:Zeng X:small:molecular:agents</idno>
<idno type="wicri:Area/Main/Merge">001502</idno>
<idno type="wicri:Area/Main/Curation">001497</idno>
<idno type="wicri:Area/Main/Exploration">001497</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Small molecular agents against MERS-CoV infection].</title>
<author><name sortKey="Zeng, Xiao Yun" sort="Zeng, Xiao Yun" uniqKey="Zeng X" first="Xiao-Yun" last="Zeng">Xiao-Yun Zeng</name>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
</author>
<author><name sortKey="Jiang, Shi Bo" sort="Jiang, Shi Bo" uniqKey="Jiang S" first="Shi-Bo" last="Jiang">Shi-Bo Jiang</name>
</author>
<author><name sortKey="Liu, Shu Wen" sort="Liu, Shu Wen" uniqKey="Liu S" first="Shu-Wen" last="Liu">Shu-Wen Liu</name>
</author>
</analytic>
<series><title level="j">Yao xue xue bao = Acta pharmaceutica Sinica</title>
<idno type="ISSN">0513-4870</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (pharmacologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Design</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Jiang, Shi Bo" sort="Jiang, Shi Bo" uniqKey="Jiang S" first="Shi-Bo" last="Jiang">Shi-Bo Jiang</name>
<name sortKey="Liu, Shu Wen" sort="Liu, Shu Wen" uniqKey="Liu S" first="Shu-Wen" last="Liu">Shu-Wen Liu</name>
<name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
<name sortKey="Zeng, Xiao Yun" sort="Zeng, Xiao Yun" uniqKey="Zeng X" first="Xiao-Yun" last="Zeng">Xiao-Yun Zeng</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001497 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001497 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27169271
   |texte=   [Small molecular agents against MERS-CoV infection].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27169271" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

Serveur d'exploration MERS

[Small molecular agents against MERS-CoV infection].

[Small molecular agents against MERS-CoV infection].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.